NO20010266D0 - Sykliske forbindelser som kan anvendes ved behandling av dyslipidemi, aterosklerose og diabetes, farmasöytiske preparater og fremstillingsfremgangsmåte - Google Patents

Sykliske forbindelser som kan anvendes ved behandling av dyslipidemi, aterosklerose og diabetes, farmasöytiske preparater og fremstillingsfremgangsmåte

Info

Publication number
NO20010266D0
NO20010266D0 NO20010266A NO20010266A NO20010266D0 NO 20010266 D0 NO20010266 D0 NO 20010266D0 NO 20010266 A NO20010266 A NO 20010266A NO 20010266 A NO20010266 A NO 20010266A NO 20010266 D0 NO20010266 D0 NO 20010266D0
Authority
NO
Norway
Prior art keywords
dyslipidemia
atherosclerosis
diabetes
treatment
pharmaceutical preparations
Prior art date
Application number
NO20010266A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010266L (no
Inventor
Jean-Jacques Berthelon
Daniel Guerrier
Eric Raspe
Jean-Jacques Zeiller
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of NO20010266L publication Critical patent/NO20010266L/no
Publication of NO20010266D0 publication Critical patent/NO20010266D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/081,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/041,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/061,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D407/00Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Pyrane Compounds (AREA)
NO20010266A 1998-07-17 2001-01-16 Sykliske forbindelser som kan anvendes ved behandling av dyslipidemi, aterosklerose og diabetes, farmasöytiske preparater og fremstillingsfremgangsmåte NO20010266D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9809164A FR2781222A1 (fr) 1998-07-17 1998-07-17 Composes cycliques utilisables dans le traitement de dyslipidemies, de l'atherosclerose et du diabete, compositions pharmaceutiques les contenant et procede de preparation
PCT/EP1999/004831 WO2000004011A1 (en) 1998-07-17 1999-07-09 Cyclic compounds useful in the treatment of dyslipidaemia, atherosclerosis and diabetes, pharmaceutical compositions and preparation process

Publications (2)

Publication Number Publication Date
NO20010266L NO20010266L (no) 2001-01-16
NO20010266D0 true NO20010266D0 (no) 2001-01-16

Family

ID=9528730

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010266A NO20010266D0 (no) 1998-07-17 2001-01-16 Sykliske forbindelser som kan anvendes ved behandling av dyslipidemi, aterosklerose og diabetes, farmasöytiske preparater og fremstillingsfremgangsmåte

Country Status (22)

Country Link
US (1) US6528538B1 (de)
EP (1) EP1098893B1 (de)
JP (1) JP2002520407A (de)
KR (1) KR20010070966A (de)
CN (1) CN1309655A (de)
AT (1) ATE235485T1 (de)
AU (1) AU753287B2 (de)
BR (1) BR9912138A (de)
CA (1) CA2337481A1 (de)
DE (1) DE69906303T2 (de)
DK (1) DK1098893T3 (de)
ES (1) ES2192853T3 (de)
FR (1) FR2781222A1 (de)
HK (1) HK1039615A1 (de)
HU (1) HUP0103411A3 (de)
ID (1) ID27854A (de)
NO (1) NO20010266D0 (de)
PL (1) PL345397A1 (de)
PT (1) PT1098893E (de)
SK (1) SK482001A3 (de)
WO (1) WO2000004011A1 (de)
ZA (1) ZA200101303B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
US7371777B2 (en) 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
EP1622569B1 (de) * 2003-04-24 2015-12-02 Incyte Corporation Aza-spiro-alkan-derivate als hemmer von metallproteasen
AP2006003688A0 (en) * 2004-01-09 2006-08-31 Cadila Healthcare Ltd 1,3-dioxane derivatives and analogues thereof useful in the treatment of I.A obesity and diabetes
WO2006018855A1 (en) * 2004-08-20 2006-02-23 Cadila Healthcare Limited Novel antidiabetic compounds
CN100389112C (zh) * 2004-12-16 2008-05-21 中国石油化工股份有限公司 一类环状缩醛和缩酮化合物及其应用
ES2327187T3 (es) * 2006-02-27 2009-10-26 Cadila Healthcare Limited Acidos 1,3-dioxano carboxilicos.
EP2019673A4 (de) * 2006-05-18 2010-06-16 Wellstat Therapeutics Corp Verbindungen zur behandlung von stoffwechselstörungen
WO2007143600A2 (en) * 2006-06-05 2007-12-13 Incyte Corporation Sheddase inhibitors combined with cd30-binding immunotherapeutics for the treatment of cd30 positive diseases
WO2016056031A1 (en) 2014-10-08 2016-04-14 Council Of Scientific & Industrial Research Novel diol compounds synthesis and its use for formal synthesis of (2r, 3 s)-3-hydroxypipecolic acid
US9637575B2 (en) 2014-12-31 2017-05-02 W. R. Grace & Co. -Conn. Catalyst system, olefin polymerization catalyst components comprising at least an internal electron donor compound, and methods of making and using the same
WO2021114207A1 (en) * 2019-12-13 2021-06-17 Rhodia Operations Production of benzene derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032536A (en) 1976-07-22 1977-06-28 Janssen Pharmaceutica N.V. (1h-benzimidazol-2-yl)carbamates
US5179216A (en) * 1990-08-16 1993-01-12 American Home Products Corporation N,n', n'-trisubstituted-5-bisaminomethylene-1,3-dioxane-4,6-dione inhibitors of acyl-coa:cholesterol-acyl transferase
TW209868B (de) * 1991-04-04 1993-07-21 Yoshitomi Pharmaceutical
DE19637840A1 (de) * 1996-09-17 1998-03-19 Henkel Kgaa Verwendung von geminalen Dialkoxyalkansäureestern zur Herstellung von desodorierenden Körperpflegemitteln

Also Published As

Publication number Publication date
EP1098893A1 (de) 2001-05-16
ATE235485T1 (de) 2003-04-15
SK482001A3 (en) 2001-09-11
ZA200101303B (en) 2002-05-15
NO20010266L (no) 2001-01-16
AU5034799A (en) 2000-02-07
FR2781222A1 (fr) 2000-01-21
CA2337481A1 (en) 2000-01-27
HUP0103411A2 (hu) 2002-04-29
PL345397A1 (en) 2001-12-17
ID27854A (id) 2001-04-26
AU753287B2 (en) 2002-10-17
EP1098893B1 (de) 2003-03-26
DE69906303D1 (de) 2003-04-30
KR20010070966A (ko) 2001-07-28
ES2192853T3 (es) 2003-10-16
DE69906303T2 (de) 2003-12-11
HK1039615A1 (zh) 2002-05-03
CN1309655A (zh) 2001-08-22
WO2000004011A1 (en) 2000-01-27
HUP0103411A3 (en) 2002-08-28
DK1098893T3 (da) 2003-07-07
US6528538B1 (en) 2003-03-04
PT1098893E (pt) 2003-08-29
JP2002520407A (ja) 2002-07-09
BR9912138A (pt) 2001-04-10

Similar Documents

Publication Publication Date Title
MXPA03009840A (es) Derivados de fenilurea sustituidos con carboxamida y metodo para la produccion de los mismos como farmacos.
NO20010266D0 (no) Sykliske forbindelser som kan anvendes ved behandling av dyslipidemi, aterosklerose og diabetes, farmasöytiske preparater og fremstillingsfremgangsmåte
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
AP2003002915A0 (en) HIV protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis.
NO20006645D0 (no) Ny form av irbesartan, fremgangsmåte for å oppnå den nevnte form og farmasöytiske preparater inneholdende den samme
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO932620L (no) Amindiol-proteaseinhibitorer
HUP0303526A2 (hu) Azetidinon-intermedier vegyületek enantioszelektiv szintézise
DE60204322D1 (de) Stickstoffmonoxid bildende zusammensetzungen zur behandlung von nagelbettinfektionen
SG130189A1 (en) Substituted indole-o-glucosides
ATE396174T1 (de) Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
EA200702674A1 (ru) Способ лечения атеросклероза, дислипидемий и связанных с ними состояний и фармацевтические композиции
SE0301368D0 (sv) Chemical compounds
DE60111362D1 (de) Stabilisierte ascorbinsäure-lösungen
DE60112330D1 (en) Pyrazolopyridinderivate
DE60211539D1 (de) Imidazopyridinderivate zur verwendung bei der behandlung von herpes-vireninfektion
DE60220525D1 (de) Pyrazolo-pyridine für die behandlung von herpes-ansteckungen
DK1206484T3 (da) Antipicornavirale forbindelser og sammensætninger, deres farmaceutiske anvendelser og materialer til deres syntese
IL165217A (en) Pesticidal pyridinecarboxamide derivatives, process for their preparation, pesticidal compositions comprising them and use thereof in the preparation of pesticidal compositions
NO20020031L (no) Dihydrobenzodiazepiner og deres anvendelse til behandling av dyslipidemi
TW200505857A (en) Chemical compounds
DK0604186T3 (da) HIV-proteaseinhibitorer, som er egnede til behandling af AIDS
HUP0000756A2 (hu) Levobupivakain vagy ropivakain alkalmazása migrén kezelésére alkalmas gyógyszerkészítmények előállítására
DE60041137D1 (de) Ceramid ähnliche verbindungen, verfahren zu deren herstellung und deren verwendung als antitumormittel
MXPA04005151A (es) Compuestos terapeuticos.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application